nach oben

International Urology and Nephrology

Erschienen in:

01.12.2015 | Nephrology - Review

Role of Smad signaling in kidney disease

verfasst von: Yanhua Zhang, Songyan Wang, Shengmao Liu, Chunguang Li, Ji Wang

Erschienen in: International Urology and Nephrology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Smads are the key intermediates of canonical transforming growth factor-beta (TGF-β) signaling. These intermediates are divided into three distinct subgroups based on their role in TGF-β family signal transduction: Receptor-regulated Smads (R-Smads) 1, 2, 3, 5 and 8, common Smad4, and inhibitory Smads6 and 7. TGF-β signaling through Smad pathway involves phosphorylation, ubiquitination, sumoylation, acetylation, and protein–protein interactions with mitogen-activated protein kinases, PI3K-Akt/PKB, and Wnt/GSK-3. Several studies have suggested that upregulation or downregulation of TGF-β/Smad signaling pathways may be a pathogenic mechanism in the progression of chronic kidney disease. Smad2 and 3 are the two major downstream R-Smads in TGF-β-mediated renal fibrosis, while Smad7 also controls renal inflammation. In this review, we characterize the role of Smads in kidney disease, describe the molecular mechanisms, and discuss the potential of Smads as a therapeutic target in chronic kidney disease.

Liu Y (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69(2):213–217. doi:10.1038/sj.ki.5000054 PubMedCrossRef

Lan HY (2008) Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 13:4984–4992PubMedCrossRef

Lan HY (2011) Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci 7(7):1056–1067PubMedCentralPubMedCrossRef

Wang W, Koka V, Lan HY (2005) Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10(1):48–56. doi:10.1111/j.1440-1797.2005.00334.x CrossRef

Hou CC, Wang W, Huang XR, Fu P, Chen TH, Sheikh-Hamad D, Lan HY (2005) Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol 166(3):761–771PubMedCentralPubMedCrossRef

Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, Morishita R, Johnson RJ (2003) Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 14(6):1535–1548PubMedCrossRef

Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, Johnson RJ, Lan HY (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J 18(1):176–178. doi:10.1096/fj.02-1117fje PubMed

Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY (2006) Essential role of Smad3 in angiotensin II—induced vascular fibrosis. Circ Res 98(8):1032–1039. doi:10.1161/01.RES.0000218782.52610.dc PubMedCentralPubMedCrossRef

Chung AC, Zhang H, Kong YZ, Tan JJ, Huang XR, Kopp JB, Lan HY (2010) Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 21(2):249–260. doi:10.1681/ASN.2009010018 PubMedCentralPubMedCrossRef

10.

Lan HY, Chung AC (2012) TGF-beta/Smad signaling in kidney disease. Semin Nephrol 32(3):236–243. doi:10.1016/j.semnephrol.2012.04.002 PubMedCrossRef

11.

Heldin CH, Moustakas A (2012) Role of Smads in TGFbeta signaling. Cell Tissue Res 347(1):21–36. doi:10.1007/s00441-011-1190-x PubMedCrossRef

12.

Meng XM, Chung AC, Lan HY (2013) Role of the TGF-beta/BMP-7/Smad pathways in renal diseases. Clin Sci (Lond) 124(4):243–254. doi:10.1042/CS20120252 CrossRef

13.

Patterson GI, Padgett RW (2000) TGF beta-related pathways. Roles in Caenorhabditis elegans development. Trends Genet 16(1):27–33PubMedCrossRef

14.

Whitman M (1998) Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev 12(16):2445–2462PubMedCrossRef

15.

Derynck R, Gelbart WM, Harland RM, Heldin CH, Kern SE, Massague J, Melton DA, Mlodzik M, Padgett RW, Roberts AB, Smith J, Thomsen GH, Vogelstein B, Wang XF (1996) Nomenclature: vertebrate mediators of TGFbeta family signals. Cell 87(2):173PubMedCrossRef

16.

Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19(23):2783–2810. doi:10.1101/gad.1350705 PubMedCrossRef

17.

Moustakas A, Souchelnytskyi S, Heldin CH (2001) Smad regulation in TGF-beta signal transduction. J Cell Sci 114(Pt 24):4359–4369PubMed

18.

Derynck R, Zhang Y, Feng XH (1998) Smads: transcriptional activators of TGF-beta responses. Cell 95(6):737–740PubMedCrossRef

19.

Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6):685–700PubMedCrossRef

20.

Ross S, Hill CS (2008) How the Smads regulate transcription. Int J Biochem Cell Biol 40(3):383–408. doi:10.1016/j.biocel.2007.09.006 PubMedCrossRef

21.

Moustakas A, Heldin CH (2009) The regulation of TGFbeta signal transduction. Development 136(22):3699–3714. doi:10.1242/dev.030338 PubMedCrossRef

22.

Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL (1998) SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell 95(6):779–791PubMedCrossRef

23.

Abdollah S, Macias-Silva M, Tsukazaki T, Hayashi H, Attisano L, Wrana JL (1997) TbetaRI phosphorylation of Smad2 on Ser465 and Ser467 is required for Smad2-Smad4 complex formation and signaling. J Biol Chem 272(44):27678–27685PubMedCrossRef

24.

Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL (1996) MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87(7):1215–1224PubMedCrossRef

25.

Souchelnytskyi S, Tamaki K, Engstrom U, Wernstedt C, ten Dijke P, Heldin CH (1997) Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling. J Biol Chem 272(44):28107–28115PubMedCrossRef

26.

Kim do Y, Kim GW, Chung SH (2013) Nectandrin A enhances the BMP-induced osteoblastic differentiation and mineralization by activation of p38 MAPK-Smad signaling pathway. Korean J Physiol Pharmacol 17(5):447–453. doi:10.4196/kjpp.2013.17.5.447 PubMedCrossRef

27.

Lin Y, Zhang B, Liang H, Lu Y, Ai X, Zhang B, Chen X (2013) JNK inhibitor SP600125 enhances TGF-beta-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner. Mol Med Rep 8(6):1623–1629. doi:10.3892/mmr.2013.1711 PubMed

28.

Matsuzaki K (2011) Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 32(11):1578–1588. doi:10.1093/carcin/bgr172 PubMedCentralPubMedCrossRef

29.

Park SH, Cho HJ, Jeong YJ, Shin JM, Kang JH, Park KK, Choe JY, Park YY, Bae YS, Han SM, Moon SK, Kim WJ, Choi YH, Chang YC (2014) Melittin inhibits TGF-beta-induced pro-fibrotic gene expression through the suppression of the TGFbetaRII-Smad, ERK1/2 and JNK-mediated signaling pathway. Am J Chin Med 42(5):1139–1152. doi:10.1142/S0192415X14500712 PubMedCrossRef

30.

Su D, Peng X, Zhu S, Huang Y, Dong Z, Zhang Y, Zhang J, Liang Q, Lu J, Huang B (2011) Role of p38 MAPK pathway in BMP4-mediated Smad-dependent premature senescence in lung cancer cells. Biochem J 433(2):333–343. doi:10.1042/BJ20100404 PubMedCrossRef

31.

Yoshida H, Kotani H, Kondo T, Tani I, Wei X, Tsuruta S, Kimura A, Asakawa M, Ito M, Nagai S, Yoshimura A (2013) CDK inhibitors suppress Th17 and promote iTreg differentiation, and ameliorate experimental autoimmune encephalomyelitis in mice. Biochem Biophys Res Commun 435(3):378–384. doi:10.1016/j.bbrc.2013.04.096 PubMedCrossRef

32.

Kaneko S, Chen X, Lu P, Yao X, Wright TG, Rajurkar M, Kariya K, Mao J, Ip YT, Xu L (2011) Smad inhibition by the Ste20 kinase Misshapen. Proc Natl Acad Sci USA 108(27):11127–11132. doi:10.1073/pnas.1104128108 PubMedCentralPubMedCrossRef

33.

Fukuchi M, Imamura T, Chiba T, Ebisawa T, Kawabata M, Tanaka K, Miyazono K (2001) Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Mol Biol Cell 12(5):1431–1443PubMedCentralPubMedCrossRef

34.

Izzi L, Attisano L (2004) Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 23(11):2071–2078. doi:10.1038/sj.onc.1207412 PubMedCrossRef

35.

Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T (2005) NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor. Biochem J 386(Pt 3):461–470. doi:10.1042/BJ20040738 PubMedCentralPubMedCrossRef

36.

Ogunjimi AA, Wiesner S, Briant DJ, Varelas X, Sicheri F, Forman-Kay J, Wrana JL (2010) The ubiquitin binding region of the Smurf HECT domain facilitates polyubiquitylation and binding of ubiquitylated substrates. J Biol Chem 285(9):6308–6315. doi:10.1074/jbc.M109.044537 PubMedCentralPubMedCrossRef

37.

Shu L, Zhang H, Boyce BF, Xing L (2013) Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration. J Bone Miner Res 28(9):1925–1935. doi:10.1002/jbmr.1938 PubMedCentralPubMedCrossRef

38.

Xin H, Xu X, Li L, Ning H, Rong Y, Shang Y, Wang Y, Fu XY, Chang Z (2005) CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem 280(21):20842–20850. doi:10.1074/jbc.M412275200 PubMedCrossRef

39.

Inoue Y, Imamura T (2008) Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 99(11):2107–2112. doi:10.1111/j.1349-7006.2008.00925.x PubMedCrossRef

40.

Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massague J, Macias MJ (2011) A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 25(12):1275–1288. doi:10.1101/gad.2060811 PubMedCentralPubMedCrossRef

41.

Ito I, Hanyu A, Wayama M, Goto N, Katsuno Y, Kawasaki S, Nakajima Y, Kajiro M, Komatsu Y, Fujimura A, Hirota R, Murayama A, Kimura K, Imamura T, Yanagisawa J (2010) Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 285(19):14747–14755. doi:10.1074/jbc.M109.093039 PubMedCentralPubMedCrossRef

42.

Simonsson M, Kanduri M, Gronroos E, Heldin CH, Ericsson J (2006) The DNA binding activities of Smad2 and Smad3 are regulated by coactivator-mediated acetylation. J Biol Chem 281(52):39870–39880. doi:10.1074/jbc.M607868200 PubMedCrossRef

43.

Tu AW, Luo K (2007) Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. J Biol Chem 282(29):21187–21196. doi:10.1074/jbc.M700085200 PubMedCrossRef

44.

Inoue Y, Itoh Y, Abe K, Okamoto T, Daitoku H, Fukamizu A, Onozaki K, Hayashi H (2007) Smad3 is acetylated by p300/CBP to regulate its transactivation activity. Oncogene 26(4):500–508. doi:10.1038/sj.onc.1209826 PubMedCrossRef

45.

Wang B, Suzuki H, Kato M (2008) Roles of mono-ubiquitinated Smad4 in the formation of Smad transcriptional complexes. Biochem Biophys Res Commun 376(2):288–292. doi:10.1016/j.bbrc.2008.08.143 PubMedCrossRef

46.

Yu F, Chou CW, Chen CC (2009) TNF-alpha suppressed TGF-beta-induced CTGF expression by switching the binding preference of p300 from Smad4 to p65. Cell Signal 21(6):867–872PubMedCrossRef

47.

Ghahhari NM, Ghahhari HM, Kadivar M (2012) Could a possible crosstalk between AMPK and TGF-beta signaling pathways be a key player in benign and malignant salivary gland tumors? Onkologie 35(12):770–774. doi:10.1159/000345131 PubMedCrossRef

48.

Moren A, Raja E, Heldin CH, Moustakas A (2011) Negative regulation of TGFbeta signaling by the kinase LKB1 and the scaffolding protein LIP1. J Biol Chem 286(1):341–353. doi:10.1074/jbc.M110.190660 PubMedCentralPubMedCrossRef

49.

Xie M, Zhang D, Dyck JR, Li Y, Zhang H, Morishima M, Mann DL, Taffet GE, Baldini A, Khoury DS, Schneider MD (2006) A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci USA 103(46):17378–17383. doi:10.1073/pnas.0604708103 PubMedCentralPubMedCrossRef

50.

Seong HA, Jung H, Ha H (2010) Murine protein serine/threonine kinase 38 stimulates TGF-beta signaling in a kinase-dependent manner via direct phosphorylation of Smad proteins. J Biol Chem 285(40):30959–30970. doi:10.1074/jbc.M110.138370 PubMedCentralPubMedCrossRef

51.

Ikushima H, Miyazono K (2012) TGF-beta signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-beta. Cell Tissue Res 347(1):37–49. doi:10.1007/s00441-011-1179-5 PubMedCrossRef

52.

Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Piccolo S (2005) Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 121(1):87–99. doi:10.1016/j.cell.2005.01.033 PubMedCrossRef

53.

He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J (2006) Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 125(5):929–941. doi:10.1016/j.cell.2006.03.045 PubMedCrossRef

54.

Dupont S, Mamidi A, Cordenonsi M, Montagner M, Zacchigna L, Adorno M, Martello G, Stinchfield MJ, Soligo S, Morsut L, Inui M, Moro S, Modena N, Argenton F, Newfeld SJ, Piccolo S (2009) FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136(1):123–135. doi:10.1016/j.cell.2008.10.051 PubMedCrossRef

55.

Agricola E, Randall RA, Gaarenstroom T, Dupont S, Hill CS (2011) Recruitment of TIF1gamma to chromatin via its PHD finger-bromodomain activates its ubiquitin ligase and transcriptional repressor activities. Mol Cell 43(1):85–96. doi:10.1016/j.molcel.2011.05.020 PubMedCrossRef

56.

Lee PS, Chang C, Liu D, Derynck R (2003) Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J Biol Chem 278(30):27853–27863. doi:10.1074/jbc.M301755200 PubMedCrossRef

57.

Liang M, Melchior F, Feng XH, Lin X (2004) Regulation of Smad4 sumoylation and transforming growth factor-beta signaling by protein inhibitor of activated STAT1. J Biol Chem 279(22):22857–22865. doi:10.1074/jbc.M401554200 PubMedCrossRef

58.

Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH (2003) SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem 278(33):31043–31048. doi:10.1074/jbc.C300112200 PubMedCrossRef

59.

Chang CC, Lin DY, Fang HI, Chen RH, Shih HM (2005) Daxx mediates the small ubiquitin-like modifier-dependent transcriptional repression of Smad4. J Biol Chem 280(11):10164–10173. doi:10.1074/jbc.M409161200 PubMedCrossRef

60.

Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A (2003) Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 63(22):7760–7768PubMed

61.

Pulaski L, Landstrom M, Heldin CH, Souchelnytskyi S (2001) Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-beta-dependent signaling but affects Smad7-dependent transcriptional activation. J Biol Chem 276(17):14344–14349. doi:10.1074/jbc.M011019200 PubMed

62.

Zhao J, Shi W, Chen H, Warburton D (2000) Smad7 and Smad6 differentially modulate transforming growth factor beta -induced inhibition of embryonic lung morphogenesis. J Biol Chem 275(31):23992–23997. doi:10.1074/jbc.M002433200 PubMedCrossRef

63.

Gronroos E, Hellman U, Heldin CH, Ericsson J (2002) Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10(3):483–493PubMedCrossRef

64.

Bai S, Shi X, Yang X, Cao X (2000) Smad6 as a transcriptional corepressor. J Biol Chem 275(12):8267–8270PubMedCrossRef

65.

Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K (1997) Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389(6651):622–626. doi:10.1038/39355 PubMedCrossRef

66.

Sangadala S, Metpally RP, Reddy BV (2007) Molecular interaction between Smurf1 WW2 domain and PPXY motifs of Smad1, Smad5, and Smad6—modeling and analysis. J Biomol Struct Dyn 25(1):11–23CrossRef

67.

Chen YK, Huang AH, Cheng PH, Yang SH, Lin LM (2013) Overexpression of Smad proteins, especially Smad7, in oral epithelial dysplasias. Clin Oral Investig 17(3):921–932. doi:10.1007/s00784-012-0756-7 PubMedCrossRef

68.

Ito Y, Zhao J, Mogharei A, Shuler CF, Weinstein M, Deng C, Chai Y (2001) Antagonistic effects of Smad2 versus Smad7 are sensitive to their expression level during tooth development. J Biol Chem 276(47):44163–44172. doi:10.1074/jbc.M011424200 PubMedCrossRef

69.

Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K (2001) Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276(16):12477–12480. doi:10.1074/jbc.C100008200 PubMedCrossRef

70.

Pot I, Bonni S (2008) SnoN in TGF-beta signaling and cancer biology. Curr Mol Med 8(4):319–328PubMedCrossRef

71.

Soond SM, Chantry A (2011) Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGFbeta signalling and EMT. Oncogene 30(21):2451–2462. doi:10.1038/onc.2010.617 PubMedCentralPubMedCrossRef

72.

Simonsson M, Heldin CH, Ericsson J, Gronroos E (2005) The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 280(23):21797–21803. doi:10.1074/jbc.M503134200 PubMedCrossRef

73.

Kitowska K, Zakrzewicz D, Konigshoff M, Chrobak I, Grimminger F, Seeger W, Bulau P, Eickelberg O (2008) Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294(1):L34–L45. doi:10.1152/ajplung.00007.2007 PubMedCrossRef

74.

Fujimoto M, Maezawa Y, Yokote K, Joh K, Kobayashi K, Kawamura H, Nishimura M, Roberts AB, Saito Y, Mori S (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305(4):1002–1007PubMedCrossRef

75.

Liu Z, Huang XR, Lan HY (2012) Smad3 mediates ANG II-induced hypertensive kidney disease in mice. Am J Physiol Renal Physiol 302(8):F986–F997. doi:10.1152/ajprenal.00595.2011 PubMedCrossRef

76.

Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A (2003) Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Investig 112(10):1486–1494. doi:10.1172/JCI19270 PubMedCentralPubMedCrossRef

77.

Zhou L, Fu P, Huang XR, Liu F, Chung AC, Lai KN, Lan HY (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 298(4):F1006–F1017. doi:10.1152/ajprenal.00675.2009 PubMedCrossRef

78.

Meng XM, Huang XR, Chung AC, Qin W, Shao X, Igarashi P, Ju W, Bottinger EP, Lan HY (2010) Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J Am Soc Nephrol 21(9):1477–1487. doi:10.1681/ASN.2009121244 PubMedCentralPubMedCrossRef

79.

Verrecchia F, Chu ML, Mauviel A (2001) Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 276(20):17058–17062. doi:10.1074/jbc.M100754200 PubMedCrossRef

80.

Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME (2006) The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J 393(Pt 2):601–607. doi:10.1042/BJ20051106 PubMedCentralPubMedCrossRef

81.

Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP, Roberts AB (2001) Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 276(23):19945–19953. doi:10.1074/jbc.M102382200 PubMedCrossRef

82.

Li J, Qu X, Yao J, Caruana G, Ricardo SD, Yamamoto Y, Yamamoto H, Bertram JF (2010) Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 59(10):2612–2624. doi:10.2337/db09-1631 PubMedCentralPubMedCrossRef

83.

Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111(19):2509–2517. doi:10.1161/01.CIR.0000165133.84978.E2 PubMedCrossRef

84.

Motazed R, Colville-Nash P, Kwan JT, Dockrell ME (2008) BMP-7 and proximal tubule epithelial cells: activation of multiple signaling pathways reveals a novel anti-fibrotic mechanism. Pharm Res 25(10):2440–2446. doi:10.1007/s11095-008-9551-1 PubMedCrossRef

85.

Wang S, Hirschberg R (2004) Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 279(22):23200–23206. doi:10.1074/jbc.M311998200 PubMedCrossRef

86.

Wang SN, Lapage J, Hirschberg R (2001) Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12(11):2392–2399PubMed

87.

Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R (2003) BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9(7):964–968. doi:10.1038/nm888 PubMedCrossRef

88.

Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC (2003) Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 284(5):F955–F965. doi:10.1152/ajprenal.00246.2002 PubMedCrossRef

89.

Kim BC, Mamura M, Choi KS, Calabretta B, Kim SJ (2002) Transforming growth factor beta 1 induces apoptosis through cleavage of BAD in a Smad3-dependent mechanism in FaO hepatoma cells. Mol Cell Biol 22(5):1369–1378PubMedCentralPubMedCrossRef

90.

Yanagisawa K, Osada H, Masuda A, Kondo M, Saito T, Yatabe Y, Takagi K, Takahashi T, Takahashi T (1998) Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene 17(13):1743–1747. doi:10.1038/sj.onc.1202052 PubMedCrossRef

91.

Tsuchida K, Zhu Y, Siva S, Dunn SR, Sharma K (2003) Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int 63(6):2000–2009. doi:10.1046/j.1523-1755.2003.00009.x PubMedCrossRef

92.

Meng XM, Huang XR, Xiao J, Chung AC, Qin W, Chen HY, Lan HY (2012) Disruption of Smad4 impairs TGF-beta/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int 81(3):266–279. doi:10.1038/ki.2011.327 PubMedCrossRef

93.

Uchida K, Nitta K, Kobayashi H, Kawachi H, Shimizu F, Yumura W, Nihei H (2000) Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis. Mol Cell Biol Res Commun 4(2):98–105. doi:10.1006/mcbr.2000.0258 PubMedCrossRef

94.

Zhao J, Miyamoto S, You YH, Sharma K (2014) AMP-activated protein kinase (AMPK) activation inhibits nuclear translocation of Smad4 in mesangial cells and diabetic kidneys. Am J Physiol Renal Physiol. doi:10.1152/ajprenal.00234.2014

95.

Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, Kitagawa M, Hishida A (2004) Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA 101(23):8687–8692. doi:10.1073/pnas.0400035101 PubMedCentralPubMedCrossRef

96.

Ka SM, Huang XR, Lan HY, Tsai PY, Yang SM, Shui HA, Chen A (2007) Smad7 gene therapy ameliorates an autoimmune crescentic glomerulonephritis in mice. J Am Soc Nephrol 18(6):1777–1788. doi:10.1681/ASN.2006080901 PubMedCrossRef

97.

Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, Lan HY (2011) The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 60(2):590–601. doi:10.2337/db10-0403 PubMedCentralPubMedCrossRef

98.

Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY (2009) Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24(5):1443–1454. doi:10.1093/ndt/gfn699 PubMedCrossRef

99.

Wang W, Huang XR, Li AG, Liu F, Li JH, Truong LD, Wang XJ, Lan HY (2005) Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 16(5):1371–1383. doi:10.1681/ASN.2004121070 PubMedCrossRef

100.

Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY (2008) Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am J Physiol Renal Physiol 295(1):F118–F127. doi:10.1152/ajprenal.00021.2008 PubMedCentralPubMedCrossRef

101.

Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY (2008) Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 19(2):233–242. doi:10.1681/ASN.2007040484 PubMedCentralPubMedCrossRef

102.

Chung AC, Huang XR, Meng X, Lan HY (2010) miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol 21(8):1317–1325. doi:10.1681/ASN.2010020134 PubMedCentralPubMedCrossRef

103.

Lancero H, Brofft JE, Downard J, Birren BW, Nusbaum C, Naylor J, Shi W, Shimkets LJ (2002) Mapping of Myxococcus xanthus social motility dsp mutations to the dif genes. J Bacteriol 184(5):1462–1465PubMedCentralPubMedCrossRef

104.

Yang F, Chung AC, Huang XR, Lan HY (2009) Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension 54(4):877–884. doi:10.1161/HYPERTENSIONAHA.109.136531 PubMedCrossRef

105.

Yang F, Huang XR, Chung AC, Hou CC, Lai KN, Lan HY (2010) Essential role for Smad3 in angiotensin II-induced tubular epithelial–mesenchymal transition. J Pathol 221(4):390–401. doi:10.1002/path.2721 PubMed

106.

Ng YY, Hou CC, Wang W, Huang XR, Lan HY (2005) Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int Suppl 94:S83–S91. doi:10.1111/j.1523-1755.2005.09421.x PubMedCrossRef

107.

Jinnin M, Ihn H, Tamaki K (2006) Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 69(2):597–607. doi:10.1124/mol.105.017483 PubMedCrossRef

108.

Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, Lin TJ, Wu CC, Lan HY, Chen A (2012) Kidney-targeting Smad7 gene transfer inhibits renal TGF-beta/MAD homologue (SMAD) and nuclear factor kappaB (NF-kappaB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 55(2):509–519. doi:10.1007/s00125-011-2364-5 PubMedCrossRef

109.

Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the microRNA perspective. Diabetes 60(7):1832–1837. doi:10.2337/db11-0082 PubMedCentralPubMedCrossRef

110.

Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY (2011) TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22(8):1462–1474. doi:10.1681/ASN.2010121308 PubMedCentralPubMedCrossRef

111.

Zhong X, Chung AC, Chen HY, Meng XM, Lan HY (2011) Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22(9):1668–1681. doi:10.1681/ASN.2010111168 PubMedCentralPubMedCrossRef

112.

Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, Natarajan R (2007) MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA 104(9):3432–3437. doi:10.1073/pnas.0611192104 PubMedCentralPubMedCrossRef

113.

Wang Q, Wang Y, Minto AW, Wang J, Shi Q, Li X, Quigg RJ (2008) MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J 22(12):4126–4135. doi:10.1096/fj.08-112326 PubMedCentralPubMedCrossRef

114.

Zhou Q, Fan J, Ding X, Peng W, Yu X, Chen Y, Nie J (2010) TGF-{beta}-induced MiR-491-5p expression promotes Par-3 degradation in rat proximal tubular epithelial cells. J Biol Chem 285(51):40019–40027. doi:10.1074/jbc.M110.141341 PubMedCentralPubMedCrossRef

115.

Kriegel AJ, Fang Y, Liu Y, Tian Z, Mladinov D, Matus IR, Ding X, Greene AS, Liang M (2010) MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res 38(22):8338–8347. doi:10.1093/nar/gkq718 PubMedCentralPubMedCrossRef

116.

Liu GX, Li YQ, Huang XR, Wei LH, Zhang Y, Feng M, Meng XM, Chen HY, Shi YJ, Lan HY (2014) Smad7 inhibits AngII-mediated hypertensive nephropathy in a mouse model of hypertension. Clin Sci (Lond) 127(3):195–208. doi:10.1042/CS20130706 CrossRef

117.

Jingushi K, Ueda Y, Kitae K, Hase H, Egawa H, Ohshio I, Kawakami R, Kashiwagi Y, Tsukada Y, Kobayashi T, Nakata W, Fujita K, Uemura M, Nonomura N, Tsujikawa K (2014) miR-629 Targets TRIM33 to Promote TGFbeta/Smad Signaling and Metastatic Phenotypes in ccRCC. Mol Cancer Res. doi:10.1158/1541-7786.MCR-14-0300

118.

Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA, Yousef GM (2013) miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34(10):2231–2239. doi:10.1093/carcin/bgt184 PubMedCrossRef

119.

Denby L, Ramdas V, Lu R, Conway BR, Grant JS, Dickinson B, Aurora AB, McClure JD, Kipgen D, Delles C, van Rooij E, Baker AH (2014) MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 25(1):65–80. doi:10.1681/ASN.2013010072 PubMedCentralPubMedCrossRef

120.

Park JT, Kato M, Lanting L, Castro N, Nam BY, Wang M, Kang SW, Natarajan R (2014) Repression of let-7 by transforming growth factor-beta1-induced Lin28 upregulates collagen expression in glomerular mesangial cells under diabetic conditions. Am J Physiol Renal Physiol 307(12):F1390–F1403. doi:10.1152/ajprenal.00458.2014 PubMedCrossRefPubMedCentral

121.

Ichii O, Yabuki A, Sasaki N, Otsuka S, Ohta H, Yamasaki M, Takiguchi M, Namiki Y, Hashimoto Y, Endoh D, Kon Y (2011) Pathological correlations between podocyte injuries and renal functions in canine and feline chronic kidney diseases. Histol Histopathol 26(10):1243–1255PubMed

122.

Leeuwis JW, Nguyen TQ, Dendooven A, Kok RJ, Goldschmeding R (2010) Targeting podocyte-associated diseases. Adv Drug Deliv Rev 62(14):1325–1336. doi:10.1016/j.addr.2010.08.012 PubMedCrossRef

123.

Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253–307. doi:10.1152/physrev.00020.2002 PubMedCrossRef

124.

Li TT, Zhang XH, Jing JF, Li X, Yang XQ, Zhu FH, Tang W, Zuo JP (2015) Artemisinin analogue SM934 ameliorates the proteinuria and renal fibrosis in rat experimental membranous nephropathy. Acta Pharmacol Sin 36(2):188–199. doi:10.1038/aps.2014.134 PubMedCentralPubMedCrossRef

125.

Wan YG, Che XY, Sun W, Huang YR, Meng XJ, Chen HL, Shi XM, Tu Y, Wu W, Liu YL (2014) Low-dose of multi-glycoside of Tripterygium wilfordii Hook. f., a natural regulator of TGF-beta1/Smad signaling activity improves adriamycin-induced glomerulosclerosis in vivo. J Ethnopharmacol 151(3):1079–1089. doi:10.1016/j.jep.2013.12.005 PubMedCrossRef

126.

Yamada S, Nakamura J, Asada M, Takase M, Matsusaka T, Iguchi T, Yamada R, Tanaka M, Higashi AY, Okuda T, Asada N, Fukatsu A, Kawachi H, Graf D, Muso E, Kita T, Kimura T, Pastan I, Economides AN, Yanagita M (2014) Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS One 9(2):e89135. doi:10.1371/journal.pone.0089135 PubMedCentralPubMedCrossRef

127.

Wang JY, Gao YB, Zhang N, Zou DW, Wang P, Zhu ZY, Li JY, Zhou SN, Wang SC, Wang YY, Yang JK (2014) miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transition by target smad7 and aggravates renal damage in diabetic nephropathy. Mol Cell Endocrinol 392(1–2):163–172. doi:10.1016/j.mce.2014.05.018 PubMedCrossRef

128.

Zhu D, Mackenzie NC, Shanahan CM, Shroff RC, Farquharson C, MacRae VE (2015) BMP-9 regulates the osteoblastic differentiation and calcification of vascular smooth muscle cells through an ALK1 mediated pathway. J Cell Mol Med 19(1):165–174. doi:10.1111/jcmm.12373 PubMedCentralPubMedCrossRef

Titel: Role of Smad signaling in kidney disease
verfasst von: Yanhua Zhang
Songyan Wang
Shengmao Liu
Chunguang Li
Ji Wang
Publikationsdatum: 01.12.2015
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 12/2015
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-015-1115-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2015

NRF2 and NF-κB mRNA expression in chronic kidney disease: a focus on nondialysis patients

Comparing the efficacy and safety of 365- and 550-μm laser fibers in semirigid ureteroscopic Ho:YAG lithotripsy

The potential repertoire of the innate immune system in the bladder: expression of pattern recognition receptors in the rat bladder and a rat urothelial cell line (MYP3 cells)

Open partial nephrectomy: ancient art or currently available technique?

Excellent graft and patient survival after renal transplantation from donors after brain death with acute kidney injury: a case–control study